OS Therapies Incorporated Common Stock (NY:OSTX)

1.620 UNCHANGED

Delayed Quote Updated: 8:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about OS Therapies Incorporated Common Stock

< Previous 1 2 3 4 5 Next >

OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update

September 30, 2025

Company updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025...

Via Newsfile

OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT

September 19, 2025

New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...

Via Newsfile

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

September 12, 2025

Clinical data from Phase 1b prostate cancer trial to be released in Q4/25Additionally, updated 2-year overall survival data from all...

Via Newsfile

Topics Death

Earnings Outlook For OS Therapies ↗

August 18, 2025

Via Benzinga

Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)

September 08, 2025

Dallas, Texas--(Newsfile Corp. - September 8, 2025) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners initiates their coverage...

Via Newsfile

OS Therapies to Participate in Upcoming Investor Conferences in September 2025

September 03, 2025

New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...

Via Newsfile

OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting

September 02, 2025

Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food &...

Via Newsfile

OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing

September 02, 2025

All remaining holders of outstanding warrants with $1.12 per share exercise price have participated, raising $3.7 million in gross proceeds...

Via Newsfile

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

August 27, 2025

New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...

Via Newsfile

OS Therapies Terminates Equity Line of Credit

August 25, 2025

New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...

Via Newsfile

Os Therapies Posts Wider Loss in Q2 ↗

August 19, 2025

Via The Motley Fool

Topics Intellectual Property

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

August 19, 2025

U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in...

Via Newsfile

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

August 14, 2025

New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...

Via Newsfile

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

August 07, 2025

66.6% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046)FDA...

Via Newsfile

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

August 07, 2025

MHRA seeks to harmonize UK & US regulatory review via Project OrbisEMA Rapporteur Scientific Advice Meeting scheduled for October 2025New...

Via Newsfile

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

July 14, 2025

Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional...

Via Newsfile

Topics Artificial Intelligence Regulatory Compliance

OS Therapies Provides Clinical & Global Regulatory Updates

July 10, 2025

End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma programScientific...

Via Newsfile

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

July 03, 2025

From OS Therapies

Via Business Wire

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

June 30, 2025

From OS Therapies

Via Business Wire

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough

June 26, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END

Via FinancialNewsMedia

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 24, 2025

From OS Therapies

Via Business Wire

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

June 23, 2025

From OS Therapies Inc.

Via Business Wire

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

June 06, 2025

From OS Therapies Inc.

Via Business Wire

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025

From OS Therapies Inc.

Via Business Wire

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

May 15, 2025

From OS Therapies

Via Business Wire

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

May 07, 2025

From OS Therapies

Via Business Wire

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

May 02, 2025

From OS Therapies

Via Business Wire

Which stocks are gapping on Monday? ↗

April 28, 2025

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

OS Therapies FDA Meeting Request Granted

April 22, 2025

From OS Therapies

Via Business Wire

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

April 10, 2025

From OS Therapies

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.